Although thrombolytic treatment dissolves clots to accelerate the resolution of PE, some authors do not support the routine use of thrombolytic agents
in subjects who were normotensive with signs of right ventricular dysfunction (24-26).
A review on successive generations of streptokinase based thrombolytic agents
[10,11] In the present study, mortality benefit seen from reteplase suggests that there should be a change in the pattern of use of thrombolytic agents
Two classifications of thrombolytic agents
are currently available in the market: nonfibrin-specific and fibrin-specific thrombolytic medications (Vaishnavi, Mohanasrinivasan, & Subathra, 2011).
The Cochrane review also indicated that differences in clinical outcome in the tPA and SK trials may not be solely related to the thrombolytic agents
In addition, among up-to-date thrombolytic agents
approved by health authorities only intravenous recombinant tissue plasminogen activator (rt-PA) is used as a systemic one.
Currently, no thrombolytic agents
have an FDA-approved indication for clearance of a thrombotic occlusion in a HD catheter.
The company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent
for vascular occlusive diseases, including acute stroke.
However, the hospitals could not agree on which type of thrombolytic agent
Developments in catheters and interventional neuroradiology techniques now offer the possibility of venous thrombolysis with either transvenous injection of a thrombolytic agent
(tPA or urokinase) into the sinus or using catheters that allow for clot retrieval (Baker et al., 2001; Buccino et al., 2001; Chow et al., 2000; Dowd, Malek, Phatourous, & Hemphill, 1999; Ekseth et al., 1998).
This reference provides treatment profiles of over 4,200 hospitals, displaying their ranking in 17 crucial areas together with their percentages against the "top hospital." For heart attack and heart failure, figures deal with aspirin on arrival and at discharge, ACE inhibitor for LVSD, Beta blocker at arrival & upon discharge, thrombolytic agent
received, PTCA received and smoking cessation advice.
Tokyo, Japan, Aug 5, 2005 - (JCNN) - Eisai has received approval for an additional indication of its thrombolytic agent
, Cleactor Inj.